A UK biotech looks to bring alliance between GSK, J&J, AstraZeneca, and top universities stateside with its first megaround
Richard Mason was working at the J&J Innovation Center in London about six years ago when the company linked arms with two other pharmas and three of the UK’s leading universities to form Apollo Therapeutics — a translational medicine group aimed at spinning out new therapies. Now he’s running the show at Apollo, and he’s pulled in $145 million to drive those programs into the clinic.
Mason unveiled what he calls Apollo’s “first institutional financing” early Thursday morning, which he plans on using to beef up operations both in the UK and the US, and advance a portfolio of more than 15 programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.